ReviewCureus2026
The Clinical Significance of the Morning Blood Pressure Surge in Chronic Kidney Disease: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morning blood pressure surge (MBPS) is a circadian blood pressure phenomenon implicated in cardiovascular and renal risk. Patients with chronic kidney disease (CKD) frequently exhibit circadian BP disturbances, but the prognostic significance of MBPS in this population remains uncertain. This systematic review evaluated the association between MBPS and clinical outcomes in adults with established CKD. A comprehensive search of major electronic databases identified observational cohort studies assessing MBPS using 24-hour ambulatory blood pressure monitoring. Studies reporting cardiovascular events, renal outcomes, or mortality were included. Two cohort studies comprising 457 patients met eligibility criteria. In one study, elevated MBPS (≥35 mmHg) was independently associated with a higher risk of composite adverse outcomes (HR 3.12; 95% CI 1.10-9.13). In the second study, elevated MBPS predicted CKD progression (HR 2.35; 95% CI 1.20-4.63) but showed no significant association with cardiovascular events or mortality. Despite differences in MBPS definitions and outcome measures, both studies demonstrated that MBPS provides independent prognostic information. Current evidence, though limited, indicates that elevated MBPS is associated with adverse renal and composite clinical outcomes in CKD. These findings support the potential utility of ambulatory BP monitoring and circadian BP assessment in risk stratification. Larger prospective studies are needed to clarify cardiovascular implications and determine whether targeting MBPS can improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.